<DOC>
	<DOC>NCT02908100</DOC>
	<brief_summary>This is a multicenter, Phase II, randomized, double-blind, placebo-controlled, parallel-group, dose-ranging study to evaluate the safety and efficacy of GDC-0853 in combination with standard of care therapy in participants with moderate to severe active systemic lupus erythematosus (SLE).</brief_summary>
	<brief_title>A Study of the Safety and Efficacy of GDC-0853 in Participants With Moderate to Severe Active Systemic Lupus Erythematosus</brief_title>
	<detailed_description />
	<mesh_term>Lupus Erythematosus, Systemic</mesh_term>
	<criteria>American College of Rheumatology (ACR) or Systemic Lupus International Collaborating Clinics (SLICC) criteria at any time prior to or at screening At least one serologic marker of SLE at screening as follows: positive antinuclear antibody (ANA) test by immunofluorescent assay with titer &gt;/= 1:80; or positive antidoublestranded DNA (antidsDNA) antibodies; or positive antiSmith antibody At both screening and Day 1, moderate to severe active SLE, defined as meeting all of the following: Safety of Estrogen in Lupus Erythematosus National AssessmentSLE Disease Activity Index (SELENASLEDAI) score &gt;/=6 (with clinical SELENASLEDAI score &gt;/= 4.0); Physician's global assessment &gt;/= 1.0 (out of 3); and currently receiving at least one standard oral treatment for SLE Participants must be willing to avoid pregnancy If on oral corticosteroids (OCS), the dose must be &lt;/= 40 mg/day prednisone (or equivalent) Stable doses of antimalarial or immunosuppressive therapies Neuropsychiatric or central nervous system lupus manifestations Estimated glomerularfiltration rate &lt; 30 millileter per minute (mL/min) or on chronic renal replacement therapy History of receiving a solid organ transplant Evidence of active, latent, or inadequately treated infection with Mycobacterium tuberculosis (TB) History of cancer, including hematological malignancy and solid tumors, within 10 years of screening Need for systemic anticoagulation with warfarin, other oral or injectable anticoagulants, or antiplatelet agents Evidence of chronic and/or active hepatitis B or C</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>